Valeo Financial Advisors LLC Purchases New Shares in Natera, Inc. $NTRA

Valeo Financial Advisors LLC purchased a new stake in Natera, Inc. (NASDAQ:NTRA) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 2,706 shares of the medical research company’s stock, valued at approximately $620,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in NTRA. Horizon Investments LLC acquired a new stake in Natera in the third quarter worth about $32,000. Flagship Harbor Advisors LLC acquired a new stake in Natera in the fourth quarter worth about $41,000. Quent Capital LLC acquired a new stake in Natera in the third quarter worth about $46,000. Sound Income Strategies LLC increased its position in Natera by 20.0% in the fourth quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock worth $62,000 after purchasing an additional 45 shares during the period. Finally, TD Waterhouse Canada Inc. acquired a new stake in Natera in the fourth quarter worth about $62,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider John Fesko sold 1,688 shares of the business’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $204.10, for a total transaction of $344,520.80. Following the completion of the transaction, the insider directly owned 187,511 shares in the company, valued at approximately $38,270,995.10. The trade was a 0.89% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Leonard Chapman sold 5,838 shares of the business’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $204.14, for a total value of $1,191,769.32. Following the transaction, the chief executive officer owned 150,769 shares of the company’s stock, valued at $30,777,983.66. The trade was a 3.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 38,266 shares of company stock valued at $7,747,808 over the last 90 days. 5.63% of the stock is owned by corporate insiders.

Natera Trading Down 4.4%

Natera stock opened at $195.32 on Thursday. The firm has a market capitalization of $27.97 billion, a P/E ratio of -119.83 and a beta of 1.57. Natera, Inc. has a 1 year low of $131.81 and a 1 year high of $256.36. The business has a 50-day moving average of $201.36 and a 200-day moving average of $215.26.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.81. The company had revenue of $665.50 million during the quarter, compared to analyst estimates of $600.68 million. Natera had a negative return on equity of 14.74% and a negative net margin of 9.05%.During the same period in the previous year, the company earned ($0.41) EPS. Research analysts anticipate that Natera, Inc. will post -1.59 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Robert W. Baird set a $265.00 price objective on Natera in a research report on Friday, May 8th. Wall Street Zen lowered Natera from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Piper Sandler reiterated an “overweight” rating and issued a $249.00 price objective on shares of Natera in a research report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research report on Tuesday, April 21st. Finally, Evercore reiterated an “outperform” rating and issued a $270.00 price objective on shares of Natera in a research report on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $256.60.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.